BioCryst Pharmaceuticals Inc. (BCRX)

Oncology Corporate Profile

Stock Performance


HQ Location

4505 Emperor Blvd, Suite 200
Durham, NC 27703

Company Description

BioCryst Pharmaceuticals is a biotechnology company that engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.


This company does not have any commercial products

This company does not have any pipeline products


Recent News Headlines

BioCryst Fails In Study For New Drug To Treat Rare Genetic Condition

2/8/2016 06:15 pm

(MarketWatch/Wall Street Journal) Feb 8, 2016 - BioCryst Pharmaceuticals Inc. on Monday reported disappointing mid-stage study results for its drug to treat a rare genetic condition characterized by swelling of the face and airways.

Smokers Who Quit More Than 15 Years Ago Need Screening

1/27/2016 07:02 am

(Mayo Clinic) Jan 26, 2016 - Expanding lung cancer screening to include people who quit smoking more than 15 years ago could detect more cases and further reduce associated mortality, according to a study by Mayo Clinic researchers published in the Journal of Thoracic Oncology.

Top U.S. Drugmakers Ride New Products To Strong Results

10/27/2015 12:04 pm

(Reuters) Oct 27, 2015 - Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck & Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits.

Senators Seek FTC Probe of Drug Makers Over Saline Shortage

10/27/2015 11:03 am

(Wall Street Journal) Oct 26, 2015 - Four U.S. senators asked the Federal Trade Commission to investigate whether suppliers of saline solution have illegally inflated prices to exploit a chronic shortage of the hospital staple.

Costs for Dementia Care Far Exceeding Other Diseases, Study Finds

10/27/2015 11:03 am

(New York Times) Oct 26, 2015 - Three diseases, leading killers of Americans, often involve long periods of decline before death. Two of them — heart disease and cancer — usually require expensive drugs, surgeries and hospitalizations. The third, dementia, has no effective treatments to slow its course.

Task Force Urges Screening Of Overweight Adults For High Blood Sugar

10/27/2015 11:03 am

(NPR/Shots blog) Oct 26, 2015 - The U.S. Preventive Services Task Force now says all overweight and obese Americans between 40 and 70 years old should get their blood sugar levels tested.

Novartis Hit By $390 Million Settlement In U.S. Kickbacks Case

10/27/2015 11:03 am

(Reuters) Oct 27, 2015 - Novartis agreed in principle to pay $390 million to settle U.S. allegations that it used kickbacks to speciality pharmacies to push sales of some drugs, the Swiss company said on Tuesday, hitting third-quarter earnings.

ASCO Says Site Neutrality Won't Cure Cancer-Care Payment Issues

10/27/2015 11:03 am

(Modern Healthcare) Oct 26, 2015 - The American Society of Clinical Oncology says the CMS should look at episode-based or bundled payment instead of site neutral payment, as federally proposed.

National Oncology Conference—Keep the Conversation Going

10/27/2015 11:02 am

(ACCCBuzz) Oct 26, 2015 - From the opening presentation by featured speaker Peter Bach, MD, MAPP, to the final sessions focused on cancer survivors and the workplace and providing survivorship services on a shoestring budget—last week’s ACCC National Oncology Conference covered challenges large and small facing cancer programs and practices across the country.

5 Things to Know About 340B

10/27/2015 11:02 am

(AJMC) Oct 23, 2015 - As the date for the comment period on the proposed guidance by HHS on 340B drug pricing draws near, read about the program and its impact on healthcare overall.

Contact White House on October 27 to Urge FDA Authority Over E-Cigarettes

10/27/2015 11:02 am

(ASCO in Action) Oct 26, 2015 - ASCO is coming together with the Campaign for Tobacco-Free Kids and other organizations to ask President Obama to finalize the deeming of the rule to give the Food and Drug Administration (FDA) the authority to regulate e-cigarettes, cigars, and hookah.

ACHC Forms Partnership with the Community Oncology Pharmacy Association (COPA)

10/27/2015 11:02 am

(WTRF-TV/Ch. 7 [Wheeling, WVA]) Oct 26, 2015 - Accreditation Commission for Health Care (ACHC) today announced a newly formed partnership with the Community Oncology Pharmacy Association (COPA). The partnership between the two organizations provides COPA members with access to special pricing options and educational resources for ACHC’s nationally recognized Pharmacy Accreditation services.

Surgery Proving Option for More Pancreatic Cancer Patients, Mayo Expert Says

10/27/2015 11:02 am

(Mayo Clinic) Oct 26, 2015 - Mayo Clinic gastrointestinal surgeon Dr. Mark Truty and his colleagues are now performing complex tumor removal operations on pancreatic cancer patients who in the past would have been considered inoperable — and they are seeing survival times rise significantly.

Lung Cancer Specialist Brings New Treatments and Hope to New Mexicans

10/27/2015 11:02 am

(UNM CCC) Oct 26, 2015 - New UNM Comprehensive Cancer Center lung cancer specialist studies biology and treatment of lung cancer through basic and clinical research.

International Oncology Expert to Lead Division in Pediatrics

10/27/2015 11:02 am

(University of Buffalo) Oct 26, 2015 - Kara Kelly, MD ’89, has been appointed chief of the Division of Hematology and Oncology in the University at Buffalo’s Department of Pediatrics, and she will lead the joint pediatric hematology and oncology program — a partnership of Women and Children’s Hospital of Buffalo, Roswell Park Cancer Institute, UB and UBMD Pediatrics.

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

10/27/2015 11:01 am

(Kite Pharma) Oct 27, 2015 - Kite Pharma, Inc. today announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences, Inc., a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer.

Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment

10/27/2015 11:01 am

(Morningstar) Oct 27, 2015 - Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens.

Thyroid Group Issues Guidelines for Kids' Nodule Management

4/24/2015 11:03 am

(MedPage Today) Apr 23, 2015 - Range of options preferred over 'one-size-fits-all' treatments.

BioCryst Expects to Begin Ebola Study in Weeks

8/29/2014 04:04 pm

(Reuters) Aug 29, 2014 - BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections.

BioCryst Hereditary Disorder Drug Succeeds in Trial, Shares Jump

5/27/2014 05:13 pm

(Reuters) May 27, 2014 - BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as much as 22 percent.

BioCryst Hereditary Disorder Drug Succeeds in Trial, Shares Jump

5/27/2014 07:01 am

(Reuters) May 27, 2014 - BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as much as 22 percent.

MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer

2/3/2014 11:05 am

(Yahoo! Finance) Feb 3, 2014 - MDxHealth SA today announced positive results from an important study designed to identify patients with aggressive prostate cancer (PCa).

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

2/3/2014 11:05 am

(Yahoo! Finance) Feb 3, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer.

BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer

2/3/2014 11:05 am

(MarketWatch) Feb 3, 2014 - Bionomics Limited has received positive results in the Phase I clinical trial of its cancer drug candidate BNC105 in women with ovarian cancer.

Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma

2/3/2014 11:05 am

(Galectin Therapeutics) Feb 3, 2014 - Galectin Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has agreed that a Phase 1B clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy® (ipilimumab) in patients with metastatic melanoma may proceed.

Pfizer Breast Cancer Drug Succeeds in Mid-stage Trial

2/3/2014 11:04 am

(Reuters) Feb 3, 2014 - Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

GlaxoSmithKline Drug Granted Breakthrough Therapy Designation

2/3/2014 11:04 am

(Wall Street Journal) Feb 3, 2014 - GlaxoSmithKline PLC has received fast-track status in the U.S. for a new application of an existing medicine to treat a rare, life-threatening blood disorder.

Cancer Cases Worldwide to Jump to 22 Million

2/3/2014 11:04 am

( Press) Feb 3, 2014 - The World Health Organization’s cancer agency warns there will be 22 million new cases of cancer every year within the next two decades.